Alcami enhances laboratory services at Wilmington, NC headquarters

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/TanawatPontchour)
(Image: iStock/TanawatPontchour)
Alcami has announced an upgrade to its laboratory service capabilities at the company’s Wilmington, NC-based headquarters.

Approximately 5,000 square feet of the current Technology Center will be converted to newly reconstructed laboratory space for dissolution testing (Apparatus I, II, III, IV and intrinsic dissolution), Karl Fischer testing (humidity controlled room), microbiology, and formulations development. 

According to the Alcami (the newly rebranded​ company combining AAI Pharma Services and Cambridge Major Labs), the new space adds 15% additional capacity for dissolution in addition to a new UV sampling automation capability.

The announcement is the latest in a series of equipment and personnel investments – since January 2015, Alcami has grown its development teams by 10% and has invested $1.6m in equipment. 

New construction, which was announced in November 2015, will bring additional laboratory capacity. One of the additional five lab spaces has been completed with the remaining labs expected to be finished by the end of the year.

Additionally, as Outsourcing-Pharma.com reported​ in March, Alcami previously announced an $11m investment in its Cortex innovation center in St. Louis, Missouri. 

Related news

Show more

Related products

show more

Powered by Ingredients + Innovation

Powered by Ingredients + Innovation

Content provided by Univar Solutions USA | 07-Oct-2024 | Product Brochure

In partnership with our industry-leading supplier partners, Univar Solutions Pharmaceutical Ingredients is proud to introduce Powering Healthy Tomorrows.

Reliability, scale, and security of supply

Reliability, scale, and security of supply

Content provided by Univar Solutions USA | 28-Aug-2024 | Product Brochure

Univar Solutions Pharmaceutical Ingredients is proud to offer one of the most expansive portfolios of 15,000+ products, including high-purity solvents,...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers

Follow us

Products

View more

Webinars